Sun Pharma to Acquire Organon in $11.75 Billion Deal
Sun Pharma is set to acquire Organon & Co. in a major all-cash transaction.
Top Summary
- What happened: Sun Pharmaceutical Industries will acquire Organon & Co. for $11.75 billion in cash.
- Why it matters: This is one of the largest overseas acquisitions by an Indian company, significantly expanding Sun Pharma's global footprint.
- What changes for people: If approved, this will bring Sun Pharma ownership of Organon, a US-based company.
- Who is affected: Sun Pharma shareholders, Organon shareholders, and potentially employees of both companies are affected.
Deal Details Unveiled
Sun Pharmaceutical Industries announced on Monday its plan to acquire US-based Organon & Co. in an all-cash transaction.
The deal is valued at $11.75 billion. This marks a significant expansion for the Indian pharmaceutical giant.
Key Acquisition Terms
Under the definitive agreement, Sun Pharma will acquire all outstanding shares of Organon.
The agreed-upon price is $14 per share, payable in cash.
Approval and Timeline
The boards of directors of both Sun Pharma and Organon have already approved the transaction.
The deal is expected to close in early 2027. However, this is subject to customary regulatory clearances and shareholder approval.
Regulatory Hurdles and Shareholder Vote
Regulatory clearances and shareholder approval are critical steps for the acquisition to proceed.
"This acquisition aligns with our strategic vision of expanding our global presence and enhancing our product portfolio,"
stated a Sun Pharma spokesperson.
What to Watch Next
Keep an eye on the progress of regulatory reviews and the shareholder vote in the coming months. The successful completion of these steps will determine the finalization of this major acquisition in early 2027.